Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (14)

2024

  1. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

2023

  1. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375

  2. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1376-1382

  3. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

  4. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis

    ESMO Open, Vol. 8, Núm. 3

2022

  1. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 29, pp. 3365-3376

2020

  1. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

    Breast Cancer Research, Vol. 22, Núm. 1

2018

  1. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 127-138

2016

  1. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1601-1610

  2. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593

2015

  1. Adjuvant ovarian suppression in premenopausal breast cancer

    New England Journal of Medicine, Vol. 372, Núm. 5, pp. 436-446

  2. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 149, Núm. 1, pp. 151-161

2014

  1. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

    New England Journal of Medicine, Vol. 371, Núm. 2, pp. 107-118

2009

  1. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

    Clinical Cancer Research, Vol. 15, Núm. 4, pp. 1452-1459